API Manufacturing Violations Compounded By Repeat Offenses, Unapproved Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA warning letters to two manufacturers of active pharmaceutical ingredients stress the need for validated procedures and fully detailed responses to inspectional observations.